Roquette completes acquisition of Qualicaps

Roquette, a leader in plant-based ingredients and pharmaceutical excipients, has completed the acquisition of Qualicaps from the Mitsubishi Chemical Group.

Qualicaps is a manufacturer of hard capsules and pharmaceutical related equipment and is the third largest producer of hard capsules for oral dosage solutions. The company has a workforce of 1,400 employees located in different sites in Asia, Europe and the Americas.

Roquette currently operates in more than 100 countries, has a turnover of around 5 billion euros, and, with this acquisition, will employ around 10,000 people worldwide.

This strategic investment offers Roquette the ability to expand the global footprint of its pharmaceutical business, as well as enrich its offerings of oral dosage solutions. Roquette’s expertise in the development of pharmaceutical excipients will be further enhanced by Qualicaps’ expertise in capsules, as well as by their assets and infrastructure.

Pierre Courduroux, CEO of Roquette, said: “This acquisition is a key milestone in our journey to reinforce our global leadership in pharmaceutical solutions and to consolidate our position in nutrition and health markets. Thanks to our combined workforce, we will continue to grow our business through collaboration with our customers and to bring our expertise and innovation to all stages of pharmaceutical development.”

Seiichiro Matsumura, CEO of Qualicaps, said: “Today marks a pivotal moment in Qualicaps’ journey. Partnering with Roquette, a renowned global leader in pharmaceutical excipients, marks the beginning of a transformative era of growth and innovation for our company. Together, we are poised to lead innovation, enrich our product portfolio, and deliver greater value to our global customer and stakeholder base. This partnership is an important step forward in our commitment to advancing healthcare solutions worldwide.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news